These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7513532)

  • 21. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
    Oesterling JE; Andrews PE; Suman VJ; Zincke H; Myers RP
    J Urol; 1993 Apr; 149(4):779-82. PubMed ID: 7681117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant hormonal therapy: the Canadian experience.
    Labrie F; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M; Tetu B; Fradet Y; Bélanger A; Candas B
    Urology; 1997 Mar; 49(3A Suppl):56-64. PubMed ID: 9123738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.
    Debruyne FM; Witjes WP; Schulman CC; van Cangh PJ; Oosterhof GO
    Eur Urol; 1994; 26 Suppl 1():4. PubMed ID: 7737257
    [No Abstract]   [Full Text] [Related]  

  • 25. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of androgen deprivation prior to radical prostatectomy for T1, T2 prostate cancer on the likelihood of curative surgery].
    Hachiya T; Kobayashi K; Ichinose T; Ishida H; Okada K
    Nihon Hinyokika Gakkai Zasshi; 1997 Nov; 88(11):936-44. PubMed ID: 9423307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
    Andros EA; Danesghari F; Crawford ED
    Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
    Fair WR; Aprikian AG; Cohen D; Sogani P; Reuter V
    Clin Invest Med; 1993 Dec; 16(6):516-22. PubMed ID: 8013156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.
    Lee F; Siders DB; McHug TA; Solomon MH; Klamerus ML
    Anticancer Res; 1997; 17(3A):1507-10. PubMed ID: 9179187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of neoadjuvant treatment prior to radical prostatectomy].
    Sassine AM; Schulman C
    Acta Urol Belg; 1992; 60(3):61-71. PubMed ID: 1492635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
    Berglund RK; Tangen CM; Powell IJ; Lowe BA; Haas GP; Carroll PR; Canby-Hagino ED; deVere White R; Hemstreet GP; Crawford ED; Thompson IM; Klein EA
    Urology; 2012 Mar; 79(3):633-7. PubMed ID: 22386416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Predictive value of the serum PSA level in patients having undergone neo-adjuvant hormone treatment before radical prostatectomy].
    Wildschutz T; Janssen T; Schulman C
    Acta Urol Belg; 1995 Mar; 63(1):79-82. PubMed ID: 7537012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.